Compare Stocks: SER, ACB, NERV, and CRDL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.03 -0.5%	$3.11	$2.56 ▼ $6.66	$261.31M	0.58	1.15 million shs	1.47 million shs
CRDL Cardiol Therapeutics	$2.17 +0.9%	$1.39	$0.88 ▼ $2.28	$251.48M	0.79	711,759 shs	2.17 million shs
NERV Minerva Neurosciences	$4.48	$4.53	$1.93 ▼ $12.46	$213.92M	-0.08	216,615 shs	82,826 shs
SER Serina Therapeutics	$2.62 +4.8%	$2.27	$1.22 ▼ $5.83	$66.55M	1.17	1.73 million shs	70,925 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+1.00%	+45.16%	+18.42%	-25.28%
CRDL Cardiol Therapeutics	+8.86%	+7.50%	+69.29%	+91.96%	+99.07%
NERV Minerva Neurosciences	-1.75%	-10.40%	+12.56%	-4.27%	+89.83%
SER Serina Therapeutics	+3.31%	-7.41%	+25.00%	+39.66%	+249,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.03 -0.5%	$3.11	$2.56 ▼ $6.66	$261.31M	0.58	1.15 million shs	1.47 million shs
CRDL Cardiol Therapeutics	$2.17 +0.9%	$1.39	$0.88 ▼ $2.28	$251.48M	0.79	711,759 shs	2.17 million shs
NERV Minerva Neurosciences	$4.48	$4.53	$1.93 ▼ $12.46	$213.92M	-0.08	216,615 shs	82,826 shs
SER Serina Therapeutics	$2.62 +4.8%	$2.27	$1.22 ▼ $5.83	$66.55M	1.17	1.73 million shs	70,925 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	0.00%	+1.00%	+45.16%	+18.42%	-25.28%
CRDL Cardiol Therapeutics	+8.86%	+7.50%	+69.29%	+91.96%	+99.07%
NERV Minerva Neurosciences	-1.75%	-10.40%	+12.56%	-4.27%	+89.83%
SER Serina Therapeutics	+3.31%	-7.41%	+25.00%	+39.66%	+249,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.50	Moderate Buy	N/A	N/A
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	360.83% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	130.65% Upside
SER Serina Therapeutics	3.00	Buy	$8.00	205.34% Upside

Current Analyst Ratings Breakdown

Latest SER, ACB, NERV, and CRDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/7/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/5/2026	ACB Aurora Cannabis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/14/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/1/2026	SER Serina Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2026	SER Serina Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$314.07M	0.83	$0.70 per share	5.77	$5.87 per share	0.69
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.47) per share	N/A
SER Serina Therapeutics	$130K	511.91	N/A	N/A	$0.74 per share	3.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	67.17	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
SER Serina Therapeutics	-$19.18M	N/A	N/A	N/A	N/A	N/A	-416.40%	-132.69%	N/A

Latest SER, ACB, NERV, and CRDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/13/2026	Q2 2026	SER Serina Therapeutics	N/A	-$0.55	N/A	-$0.55	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million
6/11/2026	Q4 2026	ACB Aurora Cannabis	-$0.07	$0.07	+$0.14	$0.86	$54.42 million	$60.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SER Serina Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
CRDL Cardiol Therapeutics	N/A	5.55	5.55
NERV Minerva Neurosciences	N/A	20.15	20.14
SER Serina Therapeutics	0.16	6.65	6.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
CRDL Cardiol Therapeutics	12.49%
NERV Minerva Neurosciences	34.56%
SER Serina Therapeutics	12.50%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
CRDL Cardiol Therapeutics	5.25%
NERV Minerva Neurosciences	1.70%
SER Serina Therapeutics	17.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	64.84 million	64.84 million	Optionable
CRDL Cardiol Therapeutics	20	115.89 million	109.80 million	Not Optionable
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable
SER Serina Therapeutics	N/A	25.40 million	20.90 million	N/A

SER, ACB, NERV, and CRDL Headlines

Recent News About These Companies

Analysts Are Bullish on These Healthcare Stocks: Tvardi Therapeutics (TVRD), GE Healthcare Technologies Inc (GEHC)

August 21, 2026 | theglobeandmail.com

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026 | globenewswire.com

Serina Therapeutics, Inc.: Serina Therapeutics Appoints Farrell Simon to its Board of Directors

July 24, 2026 | finanznachrichten.de

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 24, 2026 | globenewswire.com

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

July 23, 2026 | markets.businessinsider.com

Serina Therapeutics Amends CEO Employment and Compensation Terms

July 23, 2026 | tipranks.com

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

July 23, 2026 | globenewswire.com

Serina Therapeutics Adds Industry Veteran to Board

July 22, 2026 | tipranks.com

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

July 22, 2026 | globenewswire.com

Serina concludes sentinel dosing in Phase Ib trial’s cohort 1

July 13, 2026 | msn.com

Serina Therapeutics Inc SER

July 11, 2026 | morningstar.comM

Serina Therapeutics, Inc.: Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

July 10, 2026 | finanznachrichten.de

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

July 9, 2026 | markets.businessinsider.com

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

July 9, 2026 | globenewswire.com

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

June 30, 2026 | globenewswire.com

Serina Therapeutics Shareholders Approve Expanded Equity and Governance

June 24, 2026 | tipranks.com

Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $17,700.00 in Stock

May 27, 2026 | insidertrades.com

Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $20,101.95 in Stock

May 23, 2026 | insidertrades.com

Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks

May 16, 2026 | tipranks.com

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SER, ACB, NERV, and CRDL Company Descriptions

Aurora Cannabis NASDAQ:ACB

$4.03 -0.02 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$4.03 0.00 (-0.12%)

As of 06:05 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cardiol Therapeutics NASDAQ:CRDL

$2.17 +0.02 (+0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 +0.01 (+0.65%)

As of 05:51 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Minerva Neurosciences NASDAQ:NERV

$4.48 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$4.39 -0.09 (-1.90%)

As of 04:10 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Serina Therapeutics NYSEAMERICAN:SER

$2.62 +0.12 (+4.80%)

Closing price 04:10 PM Eastern

Extended Trading

$2.68 +0.06 (+2.48%)

As of 04:58 PM Eastern

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SER, ACB, NERV, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SER, ACB, NERV, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SER, ACB, NERV, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SER, ACB, NERV, and CRDL Company Descriptions

Aurora Cannabis NASDAQ:ACB

Cardiol Therapeutics NASDAQ:CRDL

Minerva Neurosciences NASDAQ:NERV

Serina Therapeutics NYSEAMERICAN:SER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SER, ACB, NERV, and CRDL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SER, ACB, NERV, and CRDL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SER, ACB, NERV, and CRDL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SER, ACB, NERV, and CRDL Company Descriptions

Aurora Cannabis NASDAQ:ACB

Cardiol Therapeutics NASDAQ:CRDL

Minerva Neurosciences NASDAQ:NERV

Serina Therapeutics NYSEAMERICAN:SER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools